MedTrace Logo

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

NCT02566252 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-08-10

No results posted yet for this study

Summary

This study evaluates the effect of pre-treatment with either cromolyn sodium or albuterol sulfate on the safety and tolerability or PUL-042 Inhalation Solution in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

PUL-042 Inhalation Solution

PUL-042

DRUG

Cromolyn Sodium

Pre-treatment

DRUG

Albuterol sulfate

Pre-treatment

Sponsors & Collaborators

  • WCCT Global

    collaborator INDUSTRY

  • Pulmotect, Inc.

    lead INDUSTRY

Principal Investigators

  • Michelle Ababa, MD · West Coast Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-01-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02566252 on ClinicalTrials.gov